Literature DB >> 17065575

MxA-based recognition of viral illness in febrile children by a whole blood assay.

Motokazu Nakabayashi1, Yuichi Adachi, Toshiko Itazawa, Yoshie Okabe, Hirokazu Kanegane, Mizuho Kawamura, Akihito Tomita, Toshio Miyawaki.   

Abstract

Febrile children are often given antibiotics empirically and unnecessarily. MxA is a protein induced in peripheral lymphoid cells by type 1 interferons during active viral infection. The ability of a whole blood ELISA assay for MxA to identify children with viral illness was studied in 122 children who presented with acute onset fever and 52 age-matched healthy controls. The febrile children were divided into three groups according to their final diagnoses: etiologically diagnosed viral infection, clinically diagnosed viral infection, and bacterial infection. MxA levels in the bacterial infection group and controls were similar and low (90.9 +/- 69.7 and 76.9 +/- 63.2 ng/mL, respectively). In contrast, mean MxA levels in the two viral infection groups were higher than in both the bacterial and control groups (719.2 +/- 386.4 and 827.0 +/- 651.1, respectively). A receiver operating characteristic analysis showed that the area under the curve of the MxA level was greater than under the curves of both the white blood cell count and the C-reactive protein concentration. Whole blood assay of MxA is a clinically useful tool for diagnosing viral illness in febrile children and should help reduce use of unnecessary antibiotics.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17065575     DOI: 10.1203/01.pdr.0000246098.65888.5b

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  11 in total

1.  Receptor characterization and susceptibility of cotton rats to avian and 2009 pandemic influenza virus strains.

Authors:  Jorge C G Blanco; Lioubov M Pletneva; Hongquan Wan; Yonas Araya; Matthew Angel; Raymonde O Oue; Troy C Sutton; Daniel R Perez
Journal:  J Virol       Date:  2012-11-28       Impact factor: 5.103

2.  Diagnostic accuracy of the FebriDx host response point-of-care test in patients hospitalised with suspected COVID-19.

Authors:  Tristan W Clark; Nathan J Brendish; Stephen Poole; Vasanth V Naidu; Christopher Mansbridge; Nicholas Norton; Helen Wheeler; Laura Presland; Sean Ewings
Journal:  J Infect       Date:  2020-06-21       Impact factor: 6.072

3.  Blood MxA protein as a marker for respiratory virus infections in young children.

Authors:  Laura Toivonen; Linnea Schuez-Havupalo; Maris Rulli; Jorma Ilonen; Jukka Pelkonen; Krister Melen; Ilkka Julkunen; Ville Peltola; Matti Waris
Journal:  J Clin Virol       Date:  2014-11-18       Impact factor: 3.168

Review 4.  FebriDx®: A Rapid Diagnostic Test for Differentiating Bacterial and Viral Aetiologies in Acute Respiratory Infections.

Authors:  Matt Shirley
Journal:  Mol Diagn Ther       Date:  2019-12       Impact factor: 4.476

5.  Myxovirus Resistance Protein A as a Marker of Viral Cause of Illness in Children Hospitalized with an Acute Infection.

Authors:  Ruut Piri; Mohamed Yahya; Lauri Ivaska; Laura Toivonen; Johanna Lempainen; Kirsi Nuolivirta; Lav Tripathi; Matti Waris; Ville Peltola
Journal:  Microbiol Spectr       Date:  2022-01-26

Review 6.  Virus-induced secondary bacterial infection: a concise review.

Authors:  Mohamed A Hendaus; Fatima A Jomha; Ahmed H Alhammadi
Journal:  Ther Clin Risk Manag       Date:  2015-08-24       Impact factor: 2.423

7.  Evaluation of a combined MxA and CRP point-of-care immunoassay to identify viral and/or bacterial immune response in patients with acute febrile respiratory infection.

Authors:  Robert Sambursky; Nathan Shapiro
Journal:  Eur Clin Respir J       Date:  2015-12-10

8.  Outpatient Antibiotic Stewardship: A Growing Frontier-Combining Myxovirus Resistance Protein A With Other Biomarkers to Improve Antibiotic Use.

Authors:  Patrick Joseph; Eliot Godofsky
Journal:  Open Forum Infect Dis       Date:  2018-02-15       Impact factor: 3.835

9.  Detection of Host Response to Viral Respiratory Infection by Measurement of Messenger RNA for MxA, TRIM21, and Viperin in Nasal Swabs.

Authors:  Mohamed Yahya; Maris Rulli; Laura Toivonen; Matti Waris; Ville Peltola
Journal:  J Infect Dis       Date:  2017-11-27       Impact factor: 5.226

10.  Multi-tiered screening and diagnosis strategy for COVID-19: a model for sustainable testing capacity in response to pandemic.

Authors:  Michael S Pulia; Terrence P O'Brien; Peter C Hou; Andrew Schuman; Robert Sambursky
Journal:  Ann Med       Date:  2020-05-14       Impact factor: 4.709

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.